A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Small Animal Imaging Core Bookmark and Share

Small Animal Imaging Core

The Small Animal Imaging Core (SAIC) is directed by Dr. David Colcher and staffed by Dr. James Bading (Imaging Physicist) and Desiree Crow (Core Manager).
 
Preliminary testing in laboratory animals has long had an essential role in the development of new pharmaceuticals and methods for treating human disease. The current development of sophisticated transgenic animal models as well as a growing recognition of the importance of understanding disease processes in the context of the living host has extended the use of animal experimentation beyond safety and efficacy testing into the realm of mechanistic investigation. Non-invasive imaging makes it possible to perform multiple measurements over time in the same animal, thereby enhancing data quality in studies of dynamic molecular and physiologic processes as well as greatly reducing the number of animals required for such studies.
 
During the last several years, scanners for small animals have become commercially available for all of the established modalities of medical imaging (X-ray, CT, MRI, SPECT, PET, ultrasound), as well as for optical imaging. With this technology, the dynamic biodistribution of therapeutic agents as well as vital processes such as gene expression, cell trafficking, cell viability, cell proliferation, tissue hypoxia and angiogenesis can be monitored non-invasively in the intact animal.
 
Small animal imaging has become indispensable to medical research and development and helps the investigator remain competitive for extramural funding.
 
Services
  • Providing consultation to investigators regarding the design, performance and analysis of animal imaging experiments
 
  • Ensuring proper maintenance and calibration of the equipment assigned to the laboratory
 
  • Operating the equipment assigned to the Laboratory or, where appropriate (e.g. for optical imaging equipment), training investigators or their technicians to operate the equipment
 
  • Handling, administering, surveying, tracking and disposing of radioactive materials used in imaging experiments
 
  • Ensuring that all experiments conducted within the Laboratory are performed according to approved protocols
 
Research reported in this publication included work performed in the Small Animal Imaging Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Equipment

The SAIC currently supports radionuclear, X-ray and fluorescence optical bioluminescence imaging in small animals. Imaging systems in hand include:
 
  • 2 units for optical bioluminescence (IVIS 100, Caliper)
  • 1 unit for fluorescence imaging (IUIS 100, Caliper)
  • 1 gamma camera (g IMAGER; Biospace, Inc.)
  • 1 PET scanner (microPET R4; Siemens)
  • 1 CT scanner (microCAT II Hi-Res; Siemens)
 
The microPET and microCAT are readily used in tandem to generate coregistered functional-anatomic PET/CT images. The Imaging Laboratory is also equipped with a gamma counter (Wallac Wizard 3”; Perkin-Elmer, Inc.).
 
Functional Imaging studies are conducted using a dedicated small animal gamma camera and the microPET system. Engineered antibody constructs (as well as other proteins and peptides) are being labeled with radioiodine (123I/124I) or radiometals (111In/64Cu). Planar imaging studies are being performed using125I- and123I-labeled antibody constructs and/or111In conjugated to the antibody construct using an appropriate chelate linker. The positron emission tomography (PET) studies use124I-labeled antibody constructs as well as64Cu?conjugated to the antibody construct using an appropriate chelate linker (e.g. DOTA), or18F-labeled deoxyglucose or other commercially available compounds labeled with short-lived positron-emitting radioisotopes. Labeled constructs are evaluated in biodistribution and tumor uptake studies in murine xenograft models.
 
Xenogen Biophotonic Imaging Systems
The Xenogen IVIS 100 is a non-invasive, real-time system forin vivoimaging of bioluminescence and fluorescence. In this context, bioluminescence results from enzyme-mediated chemical reactions involving injected substrates. The most commonly used enzyme/substrate combination is luciferase/luciferin. The luciferase gene is incorporated into cells so as to be constitutively (i.e., continuously) expressed for monitoring cellular growth and anatomic location. Alternatively, luciferase may be placed under the control of a promoter of interest and used as a reporter gene. When the animal is injected with luciferin, the luciferase in the cells (e.g. hematopoietic stem cells, tumor, or engineered T-cells) activates the luciferin resulting in the emission of light. Xenogen’s cooled charge-coupled device (CCD) camera system captures the resulting image and allows quantitative analysis of the acquired emissions. These images can be used to monitor cellular activity and track gene expression, the spread of a disease, and the effects of new therapeutics.
   
BiospacegIMAGER
ThegIMAGER is a high-resolution planar scintigraphic camera that combines a customized single 120 mm diameter, 4 mm thick CsI scintillation crystal with a position-sensitive photomultiplier tube to provide to a circular 100 mm diameter field of view. The thickness and composition of the crystal were optimized for use with111In. ThegIMAGER can be used with any of a series of parallel hole collimators designed for the gamma ray emissions of various radioisotopes as well as for various combinations of sensitivity and resolution. We have a collimator designed specifically for imaging mice injected with111In.
   
Small Animal PET Scanner (microPET R4)
The small animal PET scanner (microPET R4) provides fully 3-dimensional PET imaging with spatial resolution of better than 2.0 mm and quantitative accuracy for measurement of tissue activity concentration on the order of 10%. The scanner employs rings of contiguous discrete detectors. The 8 cm axial field of view is adequate for simultaneous whole body imaging of mice. Advanced image reconstruction software is available that provides resolution approaching 1.0 mm. Quantitative accuracy is supported by scatter, dead time and measured attenuation corrections. The system is controlled by a PC running under WINDOWS XT. It includes a fully developed image analysis package that supports volumetric regions of interest and fusion of PET with coregistered anatomic CT or MRI. The microPET system is a powerful instrument for studying thein vivopharmacokinetics, pharmacodynamics and efficacy of novel therapeutic agents.
   
Small-animal CT Scanner (microCAT II Ultra Hi-Res)
The new small-animal CT scanner (microCAT II Ultra Hi-Res) features a continuously tunable source that can provide x-ray peak energies from 20 to 130 kV and spatial resolution ranging from 100 mm down to 15 mm. The scanner is completely self-shielded. Its detector (phosphor screen coupled through a fiber optic light pipe to a CCD chip) is large enough to simultaneously image an entire mouse at low resolution, and the beam can be collimated to prevent exposure of tissues outside the field of interest. The unit is equipped for respiratory gating and has a video camera that enables monitoring of the animal once inside the imaging chamber. The system console is a Windows-based PC. A dedicated image reconstruction engine delivers images in “real-time”, i.e. by the end of scan for image sizes up to 512×512×512 voxels. Images are viewed on a separate, UNIX?based workstation running a powerful suite of image rendering and analysis tools under the AMIRA® package. Of particular importance is the seamless interface between the microCAT and the microPET, which are both from Siemens/CTIMI. The microCAT bed is exchangeable between the two scanners, and the microPET image viewing and analysis package (ASIPro®) supports PET-CT fusion imaging.
 

Pricing

Current service offering and pricing can be found on our iLab site. Please contact us for further questions.

Small Animal Imaging Core

Small Animal Imaging Core

The Small Animal Imaging Core (SAIC) is directed by Dr. David Colcher and staffed by Dr. James Bading (Imaging Physicist) and Desiree Crow (Core Manager).
 
Preliminary testing in laboratory animals has long had an essential role in the development of new pharmaceuticals and methods for treating human disease. The current development of sophisticated transgenic animal models as well as a growing recognition of the importance of understanding disease processes in the context of the living host has extended the use of animal experimentation beyond safety and efficacy testing into the realm of mechanistic investigation. Non-invasive imaging makes it possible to perform multiple measurements over time in the same animal, thereby enhancing data quality in studies of dynamic molecular and physiologic processes as well as greatly reducing the number of animals required for such studies.
 
During the last several years, scanners for small animals have become commercially available for all of the established modalities of medical imaging (X-ray, CT, MRI, SPECT, PET, ultrasound), as well as for optical imaging. With this technology, the dynamic biodistribution of therapeutic agents as well as vital processes such as gene expression, cell trafficking, cell viability, cell proliferation, tissue hypoxia and angiogenesis can be monitored non-invasively in the intact animal.
 
Small animal imaging has become indispensable to medical research and development and helps the investigator remain competitive for extramural funding.
 
Services
  • Providing consultation to investigators regarding the design, performance and analysis of animal imaging experiments
 
  • Ensuring proper maintenance and calibration of the equipment assigned to the laboratory
 
  • Operating the equipment assigned to the Laboratory or, where appropriate (e.g. for optical imaging equipment), training investigators or their technicians to operate the equipment
 
  • Handling, administering, surveying, tracking and disposing of radioactive materials used in imaging experiments
 
  • Ensuring that all experiments conducted within the Laboratory are performed according to approved protocols
 
Research reported in this publication included work performed in the Small Animal Imaging Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Equipment

Equipment

The SAIC currently supports radionuclear, X-ray and fluorescence optical bioluminescence imaging in small animals. Imaging systems in hand include:
 
  • 2 units for optical bioluminescence (IVIS 100, Caliper)
  • 1 unit for fluorescence imaging (IUIS 100, Caliper)
  • 1 gamma camera (g IMAGER; Biospace, Inc.)
  • 1 PET scanner (microPET R4; Siemens)
  • 1 CT scanner (microCAT II Hi-Res; Siemens)
 
The microPET and microCAT are readily used in tandem to generate coregistered functional-anatomic PET/CT images. The Imaging Laboratory is also equipped with a gamma counter (Wallac Wizard 3”; Perkin-Elmer, Inc.).
 
Functional Imaging studies are conducted using a dedicated small animal gamma camera and the microPET system. Engineered antibody constructs (as well as other proteins and peptides) are being labeled with radioiodine (123I/124I) or radiometals (111In/64Cu). Planar imaging studies are being performed using125I- and123I-labeled antibody constructs and/or111In conjugated to the antibody construct using an appropriate chelate linker. The positron emission tomography (PET) studies use124I-labeled antibody constructs as well as64Cu?conjugated to the antibody construct using an appropriate chelate linker (e.g. DOTA), or18F-labeled deoxyglucose or other commercially available compounds labeled with short-lived positron-emitting radioisotopes. Labeled constructs are evaluated in biodistribution and tumor uptake studies in murine xenograft models.
 
Xenogen Biophotonic Imaging Systems
The Xenogen IVIS 100 is a non-invasive, real-time system forin vivoimaging of bioluminescence and fluorescence. In this context, bioluminescence results from enzyme-mediated chemical reactions involving injected substrates. The most commonly used enzyme/substrate combination is luciferase/luciferin. The luciferase gene is incorporated into cells so as to be constitutively (i.e., continuously) expressed for monitoring cellular growth and anatomic location. Alternatively, luciferase may be placed under the control of a promoter of interest and used as a reporter gene. When the animal is injected with luciferin, the luciferase in the cells (e.g. hematopoietic stem cells, tumor, or engineered T-cells) activates the luciferin resulting in the emission of light. Xenogen’s cooled charge-coupled device (CCD) camera system captures the resulting image and allows quantitative analysis of the acquired emissions. These images can be used to monitor cellular activity and track gene expression, the spread of a disease, and the effects of new therapeutics.
   
BiospacegIMAGER
ThegIMAGER is a high-resolution planar scintigraphic camera that combines a customized single 120 mm diameter, 4 mm thick CsI scintillation crystal with a position-sensitive photomultiplier tube to provide to a circular 100 mm diameter field of view. The thickness and composition of the crystal were optimized for use with111In. ThegIMAGER can be used with any of a series of parallel hole collimators designed for the gamma ray emissions of various radioisotopes as well as for various combinations of sensitivity and resolution. We have a collimator designed specifically for imaging mice injected with111In.
   
Small Animal PET Scanner (microPET R4)
The small animal PET scanner (microPET R4) provides fully 3-dimensional PET imaging with spatial resolution of better than 2.0 mm and quantitative accuracy for measurement of tissue activity concentration on the order of 10%. The scanner employs rings of contiguous discrete detectors. The 8 cm axial field of view is adequate for simultaneous whole body imaging of mice. Advanced image reconstruction software is available that provides resolution approaching 1.0 mm. Quantitative accuracy is supported by scatter, dead time and measured attenuation corrections. The system is controlled by a PC running under WINDOWS XT. It includes a fully developed image analysis package that supports volumetric regions of interest and fusion of PET with coregistered anatomic CT or MRI. The microPET system is a powerful instrument for studying thein vivopharmacokinetics, pharmacodynamics and efficacy of novel therapeutic agents.
   
Small-animal CT Scanner (microCAT II Ultra Hi-Res)
The new small-animal CT scanner (microCAT II Ultra Hi-Res) features a continuously tunable source that can provide x-ray peak energies from 20 to 130 kV and spatial resolution ranging from 100 mm down to 15 mm. The scanner is completely self-shielded. Its detector (phosphor screen coupled through a fiber optic light pipe to a CCD chip) is large enough to simultaneously image an entire mouse at low resolution, and the beam can be collimated to prevent exposure of tissues outside the field of interest. The unit is equipped for respiratory gating and has a video camera that enables monitoring of the animal once inside the imaging chamber. The system console is a Windows-based PC. A dedicated image reconstruction engine delivers images in “real-time”, i.e. by the end of scan for image sizes up to 512×512×512 voxels. Images are viewed on a separate, UNIX?based workstation running a powerful suite of image rendering and analysis tools under the AMIRA® package. Of particular importance is the seamless interface between the microCAT and the microPET, which are both from Siemens/CTIMI. The microCAT bed is exchangeable between the two scanners, and the microPET image viewing and analysis package (ASIPro®) supports PET-CT fusion imaging.
 

Pricing

Pricing

Current service offering and pricing can be found on our iLab site. Please contact us for further questions.
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media
 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 


NEWS & UPDATES
  • Patients with metastatic colorectal cancer often stop responding to the primary drugs used against the disease, leaving them with few options and little hope. Determined to increase those options, doctors and researchers at City of Hope are conducting two clinical trials that could lead to new treatments for pe...
  • Investigators working at City of Hope are making many significant inroads against many forms of cancer. To do that, they have to take a variety of approaches. Molecular oncology researchers focus on abnormal cancer-associated activity in a cell’s nucleus. One especially prominent factor in many breast and ovari...
  • In light of the new breast cancer screening guidelines, which call for women to have mammograms every other year from age 50 to 74, it’s more important than ever for women to understand their individual risk. On Monday, the U.S. Preventive Services Task force released new breast cancer screening guideline...
  • Cancer patients need, and deserve, more than medical care. They and their families need high-quality supportive care – that is, care that addresses their physical, emotional and spiritual well-being. Health care professionals increasingly understand this, but starting such programs from scratch isn’t easy...
  • Each year, City of Hope patients given another chance at life gather to pose for a picture like this one. Going on its 39th year, the celebration of patients free of blood cancers thanks to bone marrow or stem cell transplants has grown such that a photographer has to scale a cherry picker just to […]
  • Cancer patients who are participating in early-stage clinical trials need extra emotional and physical support due to their additional stress and often unique symptoms. Now an effort by researchers at City of Hope to create a model for such support has received a $6.8 million grant from the National Cancer Inst...
  • The need for improvements in treating malignant brain tumors has never been greater. Survival for many patients with these tumors are sometimes measured in just months. One reason that therapeutic options are limited is that traditional surgery is deemed too risky for many brain tumors, especially for those in ...
  • “Honestly, there’s nothing special about my story,” protested Daniel Samson, as he bounced Layla, his 3 1/2-year-old daughter, on his lap and put on a video for her to watch. “I just want to tell it for my own sake, and share it with other men who may be going through this chaos.” Samson spoke […]
  • As far back as he can remember, Jonathan Yamzon, M.D., wanted to be a doctor. “I knew it from the get-go,” he said, matter-of-factly. “I always envisioned it as the ideal; the supreme thing one could do with one’s life.” The youngest of six children, Yamzon was barely a toddler when his family moved to [&...
  • There’s never a “good” time for cancer to strike. With testicular cancer, the timing can seem particularly unfair. This disease targets young adults in the prime of life; otherwise healthy people unaccustomed to any serious illness, let alone cancer. And suddenly … “I can only imagine what they must...
  • Sure, a healthy lifestyle can lower a person’s risk, but the impact of specific actions is harder to tease out. Diet, exercise, tobacco use, nutritional supplements, alcohol consumption … How important are each of these factors, individually? Does strict adherence to (or rejection of) one get you a pass o...
  • Health care decisions are tough. They’re even tougher when you – or loved ones – have to make them without a plan or a conversation. National Healthcare Decisions Day, on April 16,  is a nationwide initiative to demystify the health care decision-making process and encourage families to start talking. Ult...
  • The statistics, direct from the American Cancer Society, are sobering: Cancer death rates among African-American men are 27 percent higher than for white men. The death rate for African-American women is 11 percent higher compared to white women. Hispanics have higher rates of cervical, liver and stomach cancer...
  • “Lucky” is not usually a term used to describe someone diagnosed with cancer.  But that’s how 34-year-old Alex Camargo’s doctor described him when he was diagnosed with thyroid cancer — the disease is one of the most treatable cancers at all stages. That doctor was ultimately proved righ...
  • Geoff Berman, 61, starts his day with the motto: “The sun is up. I’m vertical. It’s a good day.” Ever since he’s been in remission from lymphoma, Berman makes a special point of being grateful for each day, reminding himself that being alive is a gift. “I just enjoy living,” he said. “I give e...